Form 8-K - Current report:
SEC Accession No. 0001193125-26-167512
Filing Date
2026-04-22
Accepted
2026-04-21 18:45:14
Documents
10
Period of Report
2026-04-21
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kytx-20260421.htm   iXBRL 8-K 48110
2 EX-99.1 kytx-ex99_1.htm EX-99.1 59084
  Complete submission text file 0001193125-26-167512.txt   224292

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kytx-20260421.xsd EX-101.SCH 24834
13 EXTRACTED XBRL INSTANCE DOCUMENT kytx-20260421_htm.xml XML 4717
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41947 | Film No.: 26880882
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)